Sirolimus protein-bound

Generic name: Sirolimus Protein-bound
Brand names: Fyarro
Dosage form: intravenous powder for injection (100 mg)
Drug class: MTOR inhibitors

Usage of Sirolimus protein-bound

Sirolimus protein-bound is used to treat adults with a certain type of perivascular epithelioid cell tumor (PEComa).

Sirolimus protein-bound may also be used for purposes not listed in this medication guide.

Sirolimus protein-bound side effects

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Sirolimus protein-bound may cause serious side effects. Call your doctor at once if you have:

sudden chest pain, wheezing, dry cough, feeling short of breath;

nosebleeds, bleeding gums, abnormal vaginal bleeding, any bleeding that will not stop;

low blood potassium--leg cramps, constipation, irregular heartbeats, fluttering in your chest, increased thirst or urination, numbness or tingling, muscle weakness or limp feeling;

signs of infection--fever, chills, sore throat, body aches, unusual tiredness, loss of appetite, bruising or bleeding; or

low blood cell counts--fever, chills, tiredness, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands and feet, feeling light-headed or short of breath.

Common side effects of sirolimus protein-bound may include:

blisters or ulcers in your mouth, red or swollen gums, trouble swallowing;

fever, chills, sore throat, body aches, loss of appetite, bruising or bleeding;

tiredness;

cough;

altered sense of taste;

rash;

nausea, diarrhea, vomiting;

swelling;

muscle, bone, or joint pain; or

loss of weight and appetite.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Sirolimus protein-bound

You should not use sirolimus protein-bound if you are allergic to it, other rapamycin derivatives, or albumin.

Tell your doctor if you have ever had:

liver disease;

diabetes;

breathing problems; or

bleeding problems.

Both men and women using this medicine should use effective birth control to prevent pregnancy. Sirolimus protein-bound can harm an unborn baby if the mother or father is using this medicine.

Keep using birth control for at least 12 weeks after your last dose. Tell your doctor right away if a pregnancy occurs.

You will need to have a negative pregnancy test before starting this treatment.

Sirolimus protein-bound may affect fertility in men or women. Pregnancy could be harder to achieve while either parent is using this medicine.

Do not breastfeed while using this medicine, and for at least 2 weeks after your last dose.

Relate drugs

How to use Sirolimus protein-bound

Usual Adult Dose for Malignant perivascular epithelioid cell neoplasm:

Recommended dose: 100 mg/m2 as an IV infusion over 30 minutes on Days 1 and 8 of each 21-day cycle.Duration of therapy: Until disease progression or unacceptable toxicityUse: Adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa)

Warnings

Both men and women using sirolimus protein-bound should use effective birth control to prevent pregnancy. Sirolimus protein-bound can harm an unborn baby if the mother or father is using this medicine.

What other drugs will affect Sirolimus protein-bound

Sometimes it is not safe to use certain medicines at the same time. Some drugs can affect your blood levels of other drugs you use, which may increase side effects or make the medicines less effective.

Other drugs may affect sirolimus protein-bound, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.